[Improvement of musculoskeletal function by cell-based therapy using mesenchymal stem cells with a prolonged life span].
Umezawa A., Terai M.
Animal Study, published in Clin Calcium (2005) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Clin Calcium (2005)
- Country
- Japan
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 15876743
Abstract (original English)
Cell transplantation has recently been attempted to improve musculoskeletal function. Many types of cells, such as embryonic stem cells, fetal cardiomyocytes, myoblasts, bone marrow hematopoietic cells, and mesenchymal stem cells (MSCs), have been transplanted to functionally restore damaged or diseased tissue in animal models, and marrow-derived mononuclear cells have been injected into ischemic limb clinically. MSCs can be a useful source of cell transplantation for several reasons:they have the ability to proliferate and differentiate into mesodermal tissues, including myocytes, they entail no ethical or immunological problems, and bone marrow aspiration is an established routine procedure. When placed in appropriate in vitro and in vivo environments, MSCs can give rise to all major mesenchymal tissues, such as bone, cartilage, muscle, and adipose tissue. Direct injection of murine and porcine MSCs into skeletal muscles has been shown to be feasible in murine models of ischemic limb. Large numbers of cells must be injected into damaged sites in ischemic limb to restore muscular function in humans, and cells need to be injected into the entire limb. Until now, however, there have been no reports of a sufficient number of differentiated human myocytes ever having been obtained to restore muscular function of ischemic limb. One of the reasons for this is that the life span of h
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.